Wedbush Reiterates Outperform Rating for Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (NASDAQ:KPTI)‘s stock had its “outperform” rating reaffirmed by analysts at Wedbush in a report released on Tuesday. They currently have a $14.00 price target on the stock. Wedbush’s price target points to a potential upside of 50.21% from the company’s previous close.
Other analysts also recently issued reports about the company. S&P Equity Research lowered their price objective on Karyopharm Therapeutics from $9.06 to $7.55 in a research note on Tuesday, August 30th. Jefferies Group reissued a “buy” rating and issued a $12.00 price objective on shares of Karyopharm Therapeutics in a research note on Thursday, September 8th. HC Wainwright increased their price objective on Karyopharm Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, September 8th. Vetr downgraded Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating and set a $11.00 price objective for the company. in a research note on Wednesday, August 31st. Finally, Canaccord Genuity set a $20.00 price objective on Karyopharm Therapeutics and gave the stock a “buy” rating in a research note on Saturday, August 6th. Two equities research analysts have rated the stock with a sell rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $16.04.
Karyopharm Therapeutics (NASDAQ:KPTI) opened at 9.32 on Tuesday. Karyopharm Therapeutics has a 52 week low of $4.83 and a 52 week high of $19.41. The stock’s 50 day moving average price is $8.70 and its 200 day moving average price is $8.27. The company’s market capitalization is $335.42 million.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Monday, November 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.12. Analysts anticipate that Karyopharm Therapeutics will post ($3.22) earnings per share for the current year.
Hedge funds have recently added to or reduced their stakes in the company. BlackRock Advisors LLC increased its stake in Karyopharm Therapeutics by 15.1% in the third quarter. BlackRock Advisors LLC now owns 11,410 shares of the company’s stock worth $111,000 after buying an additional 1,498 shares in the last quarter. Metropolitan Life Insurance Co. NY purchased a new stake in Karyopharm Therapeutics during the second quarter worth about $136,000. Emerald Acquisition Ltd. increased its stake in Karyopharm Therapeutics by 46.2% in the third quarter. Emerald Acquisition Ltd. now owns 14,327 shares of the company’s stock worth $139,000 after buying an additional 4,527 shares in the last quarter. Nationwide Fund Advisors increased its stake in Karyopharm Therapeutics by 38.3% in the second quarter. Nationwide Fund Advisors now owns 21,258 shares of the company’s stock worth $143,000 after buying an additional 5,886 shares in the last quarter. Finally, Endurance Wealth Management Inc. increased its stake in Karyopharm Therapeutics by 166.7% in the third quarter. Endurance Wealth Management Inc. now owns 16,000 shares of the company’s stock worth $156,000 after buying an additional 10,000 shares in the last quarter. 55.71% of the stock is owned by institutional investors and hedge funds.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.
Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.